Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans

References

• Stovner LJ, Hagen K. Prevalence, burden, and cost of headache disorders. Curr Opin Neurol 2006;19:281–5
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005;45 Suppl 1:S3–13
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436–42
   PubMed Web of Science ®Google Scholar
• Valade D. Headaches in the emergency room. In: Olesen J, Goadsby PJ, Ramadan NM, et al., eds. The Headaches, 3rd edn. Baltimore: Lippincott, Williams & Wilkins, 2006: 1133–8
   Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754–62
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Tepper SJ, Dahlof C. Patients’ preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine. J Headache Pain 2005;6:112–20
   Google Scholar
• Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache 2006;46 Suppl 4:S212–20
   PubMed Web of Science ®Google Scholar
• Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache 1997;37:S15–25
   PubMed Web of Science ®Google Scholar
• Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006;46:S171–81
   PubMed Web of Science ®Google Scholar
• Ala-Hurula V. Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine. Eur J Clin Pharmacol 1982;21:397–402
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Paalzow L. Intramuscular ergotamine: plasma levels and dynamic activity. Clin Pharmacol Ther 1985;37:29–35
   PubMed Web of Science ®Google Scholar
• Borgstrom L, Bengtsson T, Derom E, Pauwels R. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler. Int J Pharmaceutics 2000;193:227–30
   PubMed Web of Science ®Google Scholar
• Newman SP. Variability in drug delivery from aerosol inhalers in vitro and in vivo. In: Dalby RN, Byron PR, Farr SJ, eds. Respiratory Drug Delivery V. Buffalo Grove: Interpharm Press, 1996:11–18
   Google Scholar
• Snell NJC, Ganderton D. Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, UK on 17 April 1998. Respir Med 1999;93: 123–33
   Google Scholar
• Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers. Eur J Clin Pharmacol 1982;23:235–40
   Google Scholar
• Sanders SW, Haering N, Mosberg H, Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol 1986;30:331–4
   PubMed Web of Science ®Google Scholar
• Ekbom K, Krabbe AE, Paalzow G, et al. Optimal routes of administration of ergotamine tartrate in cluster headache patients. A pharmacokinetic study. Cephalalgia 1983;3:15–20
   PubMed Web of Science ®Google Scholar
• Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. American Academy of Neurology Practice Guideline 2000. (Available at http//www.neurology.org, April 2000; last accessed January 22, 2007)
   Google Scholar
• Mondell BE. A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine. Clin Ther 2003;25:331–41
   PubMed Web of Science ®Google Scholar
• Newman SP, Clark AR, Talaee N, Clarke SW. Pressurised aerosol deposition in the human lung with and without an ‘open’ spacer. Thorax 1989;44:706–10
   PubMed Web of Science ®Google Scholar
• Newman SP. Characteristics of radiolabelled versus unlabelled formulations. J Aerosol Med 1996;9 Suppl 1:S37–47
   PubMedGoogle Scholar
• Newman SP, Weisz AWB, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991;46:712–16
   PubMed Web of Science ®Google Scholar
• Newman SP, Steed KP, Hooper G, et al. Improved targeting of beclomethasone dipropionate (250 μg metered dose inhaler) to the lungs of asthmatics with the Spacehaler. Respir Med 1999;93:424–31
   PubMed Web of Science ®Google Scholar
• Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med 1996;9:55–70
   PubMedGoogle Scholar
• Newman SP. Spacer devices for metered dose inhalers. Clin Pharmacokinetics 2004;43:349–60
   PubMed Web of Science ®Google Scholar
• Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12:1346–53
   Google Scholar
• Newman SP, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006;100: 375–84
   PubMed Web of Science ®Google Scholar
• Börgstrom L Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med 2006;19:473–83
   Google Scholar
• Newman SP, Hirst PH, Pitcairn GR, Clark AR. Understanding regional lung deposition in gamma scintigraphy. In: Dalby RN, Byron PR, Farr SJ, eds. Respiratory Drug Delivery VI. Buffalo Grove: Interpharm Press, 1998:9–15
   Google Scholar